MIGNONE ROBERTO 4

What Happened

• Roberto Mignone, a director of Teva Pharmaceutical Industries Ltd (TEVA), had 14,492 derivative units convert into ordinary shares on June 5, 2026. The filing shows an acquisition of 14,492 shares (exercise/conversion) and a simultaneous disposition of 14,492 shares at $0.00. The acquisition value is listed as N/A and the disposition shows $0 proceeds, so there were no cash proceeds reported from the disposed shares.

Key Details

• Transaction date: June 5, 2026 (reported on Form 4 filed June 8, 2026) — filing appears timely.
• Transaction code: M = Exercise or conversion of a derivative security.
• Shares acquired: 14,492 (conversion/exercise); Shares disposed: 14,492 at $0.00 (no cash proceeds).
• Shares reported in Table I: 367,600 Ordinary Shares are held of record by Swiftcurrent Master Fund Ltd.; Bridger Management, LLC is the fund’s adviser and Mr. Mignone is the manager. By rule, he may be deemed to beneficially own those shares but he disclaims beneficial ownership except to the extent of any indirect pecuniary interest.
• Relevant footnotes:
  • F1: Ordinary shares may be represented by American Depositary Shares (1 ADS = 1 Ordinary Share).
  • F2: Each restricted share unit (RSU) converts to one ordinary share or cash at settlement.
  • F4: The RSUs were granted June 5, 2025 and vested June 5, 2026.
• Filing timeliness: Event on 6/5 and Form 4 filed 6/8; no late filing flag in the report.

Context

• The filing indicates conversion/settlement of vested restricted share units (per footnotes) rather than an open-market buy or sale. The simultaneous $0 disposition commonly reflects shares withheld or surrendered for tax withholding or net settlement at vesting rather than a market sale (the filing does not specify the exact reason). Because the acquired shares were immediately surrendered, there is no net increase in publicly reported shares held by Mr. Mignone from this transaction.